18F-FDG PET/CT reveals disease remission in a patient with ipilimumab-refractory advanced melanoma treated with pembrolizumab

• Verfasst von: Sachpekidis, Christos [VerfasserIn]
• Verfasst von: Hassel, Jessica C. [VerfasserIn]
• Verfasst von: Dimitrakopoulou-Strauss, Antonia [VerfasserIn]
• Titel: 18F-FDG PET/CT reveals disease remission in a patient with ipilimumab-refractory advanced melanoma treated with pembrolizumab
• Verf.angabe: Christos Sachpekidis, Jessica C. Hassel, and Antonia Dimitrakopoulou-Strauss
• E-Jahr: 2016
• Jahr: February 2016
• Umfang: 3 S.
• Fussnoten: Gesehen am 07.05.2020
• Titel Quelle: Enthalten in: Clinical nuclear medicine
• Ort Quelle: Philadelphia, Pa. : Lippincott Williams & Wilkins, 1976
• Jahr Quelle: 2016
• Band/Heft Quelle: 41(2016), 2, Seite 156-158
• ISSN Quelle: 1536-0229
• DOI: doi:10.1097/RLU.0000000000001039
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 169765889X

Abstract

Pembrolizumab is an anti-programmed cell death receptor 1 (anti-PD-1) antibody, recently approved for the treatment of ipilimumab-refractory metastatic melanoma. We report on a 49-year-old patient with unresectable metastatic melanoma initially treated with 4 cycles of ipilimumab. Because of demonstration of progressive disease on PET/CT, the patient was enrolled into a clinical trial of pembrolizumab. After completion of 4 cycles of pembrolizumab, the follow-up PET/CT scans performed early after and 7 months after the end of treatment exhibited complete disease remission, reflecting the potential role of the modality in treatment response evaluation of melanoma patients receiving anti-PD-1 therapy.